Menu Search
Equities

Modalis Therapeutics Corp

4883:TYO

Modalis Therapeutics Corp

Actions
  • Price (JPY)101.00
  • Today's Change-7.00 / -6.48%
  • Shares traded8.35m
  • 1 Year change-34.42%
  • Beta0.6773
Data delayed at least 20 minutes, as of Sep 20 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in JPYIncome statement in JPYView more

Year on year Modalis Therapeutics Corp had revenues fall -100.00% from 40.50m to 0.00, though the company grew net income from a loss of 2.70bn to a smaller loss of 2.39bn.
Gross margin--
Net profit margin--
Operating margin--
Return on assets-100.32%
Return on equity-117.39%
Return on investment-110.17%
More ▼

Cash flow in JPYView more

In 2023, cash reserves at Modalis Therapeutics Corp fell by 1.05bn. Cash Flow from Financing totalled 1.22bn or -- of revenues. In addition the company used 2.25bn for operations while cash used for investing totalled 39.70m.
Cash flow per share-63.23
Price/Cash flow per share--
Book value per share28.21
Tangible book value per share28.21
More ▼

Balance sheet in JPYView more

Modalis Therapeutics Corp appears to have little financial risk as the company holds a substantial amount of cash on its books. In fact, 0.32% of the market capitalization can be attributed to its 1.88bn and debt could be paid in full if management chose.
Current ratio12.91
Quick ratio12.87
Total debt/total equity0.146
Total debt/total capital0.1274
More ▼

Growth rates in JPY

Year on year, growth in earnings per share excluding extraordinary items increased 16.82%.
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		36.20
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.